Semaglutide use in people with obesity and type 2 diabetes from real‐world utilization data: An analysis of the All of US Program

Author:

Mayer Craig S.1ORCID,Fontelo Paul1

Affiliation:

1. Lister Hill National Center for Biomedical Communications, National Library of Medicine, National Institutes of Health Bethesda Maryland USA

Abstract

AbstractAimTo analyse data from the All of Us Research Program to evaluate the real‐world application and long‐term effectiveness of semaglutide in treating type 2 diabetes and obesity patients in a large population.Materials and MethodsWe identified patients prescribed semaglutide and analysed differences in route of administration and the time on semaglutide. For individuals diagnosed with obesity, we measured changes in body mass index (BMI) and weight from baseline, while measured changes in HbA1c for those patients with type 2 diabetes. We also examined the occurrence of newly diagnosed common adverse events from taking semaglutide.ResultsFor 3739 semaglutide patients, those on injectable semaglutide (3364 patients) averaged 301.54 days on the medication, with 20.36% having no end date, while those on oral semaglutide (435 patients) averaged 172.48 days, with 24.60% having no end date. We found average decreases of 1.54 kg/m2 in BMI, 4.65 kg in weight and 0.75% in HbA1c for semaglutide users. The decreases were larger in participants taking injectable formulation, probably because of higher starting values. Over time, improvements in these outcomes diminished, but the values remained significantly lower than baseline levels. Approximately only 1.0% of patients reported newly diagnosed common adverse events.ConclusionsConsistent with clinical trial findings, this real‐world data analysis showed that semaglutide was well tolerated and that, for a large population, it effectively reduced BMI, body weight and HbA1c, albeit to smaller magnitudes than observed in clinical trials. These findings provide valuable insights into real‐world experience and the long‐term effectiveness of semaglutide.

Funder

U.S. National Library of Medicine

Publisher

Wiley

Reference22 articles.

1. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

2. Diabetes[Internet]. [cited 2024 Aug 9]. Available from:https://www.who.int/news-room/fact-sheets/detail/diabetes

3. Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends

4. Safety of Semaglutide

5. Semaglutide Injection: MedlinePlus Drug Information[Internet]. [cited 2024 Aug 9]. Available from:https://medlineplus.gov/druginfo/meds/a618008.html

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3